Results 11 to 20 of about 11,686 (228)

Pretreatment with VEGF(R)-inhibitors reduces interstitial fluid pressure, increases intraperitoneal chemotherapy drug penetration, and impedes tumor growth in a mouse colorectal carcinomatosis model [PDF]

, 2015
Cytoreductive surgery combined with intraperitoneal chemotherapy (IPC) is currently the standard treatment for selected patients with peritoneal carcinomatosis of colorectal cancer.
Ceelen, Wim, De Wever, Olivier, Descamps, Benedicte, Gremonprez, Félix, Izmer, Andrei, Vanhaecke, Frank, Vanhove, Christian   +6 more
core   +7 more sources

Cytoreduction and HIPEC in the treatment of "unconventional" secondary peritoneal carcinomatosis [PDF]

, 2015
BACKGROUND: Peritoneal metastasis (PM) is considered a terminal and incurable disease. In the last 30 years, cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) radically changed the therapeutic approach for these patients ...
Accarpio, Fabio, Biacchi, Daniele, Cardi, Maurizio, DI GIORGIO, Angelo, Mingarelli, Valentina, Musio, Daniela, Sammartino, Paolo, Sibio, Simone, Sollazzo, BIANCA MARIA   +8 more
core   +2 more sources

Hyperthermic intraperitoneal chemotherapy (HIPEC) after primary debulking surgery in advanced epithelial ovarian cancer: Is BRCA mutational status making the difference?

Cancer Treatment and Research Communications, 2022
Introduction: The role of a molecular pattern predictive of hyperthermic intraperitoneal chemotherapy (HIPEC) efficacy in advanced ovarian cancer (AOC) patients has been poorly investigated.
Valentina Ghirardi, Francesca De Felice, Marco D'Indinosante, Federica Bernardini, Maria Teresa Giudice, Anna Fagotti, Giovanni Scambia   +6 more
doaj   +1 more source

Prognostic factors influencing infectious complications after cytoreductive surgery and HIPEC. Results from a tertiary referral center [PDF]

, 2019
Background. Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) showed promising results in selected patients. High morbidity restrains its wide application.
Carbonari, Ludovica, Cardi, Maurizio, D'Agostino, Claudia, Fonsi, Giovanni Battista, Francesco Di Marzo,, Francesco, Lefoche, LA TORRE, Giuseppe, Sammartino, Paolo, Sibio, Simone   +8 more
core   +1 more source

The efficacy of traditional chinese medicine combined with hyperthermic intraperitoneal chemotherapy for malignant ascites: A systematic review and meta-analysis

Frontiers in Pharmacology, 2022
Objective: Malignant ascites (MA) is a common complication of terminal cancer, which seriously affects the life quality and prognosis of patients. Both hyperthermic intraperitoneal chemotherapy (HIPEC) and traditional Chinese medicine (TCM) preparations ...
Zhixian Lin, Jiangfeng Chen, Yunxia Liu
doaj   +1 more source

Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy for patients with peritoneal metastases from endometrial cancer [PDF]

, 2017
Background: More information is needed for selection of patients with peritoneal metastases from endometrial cancer (EC) to undergo cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC). Methods: This study analyzed clinical,
Biacchi, Daniele, Christopoulou, Athina, Ciardi, Antonio, Cornali, Tommaso, Efstathiou, Elias, Framarino dei Malatesta, Marialuisa, Kopanakis, Nikolaos, Sammartino, Paolo, Spagnoli, Alessandra, Spiliotis, John   +9 more
core   +1 more source

Modeling of Chemoperfusion vs. Intravenous Administration of Cisplatin in Wistar Rats: Adsorption and Tissue Distribution

Molecules, 2020
Hyperthermic intraperitoneal chemoperfusion (HIPEC) is an established form of locoregional chemotherapy of peritoneum tumors. However, its efficacy and safety status remain a controversy, partially, due to scarce data on pharmacokinetics and toxicity ...
Galina Kireeva, Stepan Kruglov, Mikhail Maydin, Ekaterina Gubareva, Elena Fedoros, Ekaterina Zubakina, Natalya Ivanenko, Marina Bezruchko, Nikolay Solovyev   +8 more
doaj   +1 more source

Interval debulking surgery with or without hyperthermic intraperitoneal chemotherapy in advanced-stage ovarian cancer: Single-institution cohort study

Frontiers in Oncology, 2022
To evaluate the additive effects of hyperthermic intraperitoneal chemotherapy (HIPEC) to interval debulking surgery (IDS) in patients with advanced-stage ovarian cancer.
Yong Jae Lee, Ki Eun Seon, Dae Chul Jung, Jung-Yun Lee, Eun Ji Nam, Sang Wun Kim, Sunghoon Kim, Young Tae Kim   +7 more
doaj   +1 more source

The Global End-Diastolic Volume (GEDV) Could Be More Appropiate to Fluid Management Than Central Venous Pressure (CVP) During Closed Hyperthermic Intrabdominal Chemotherapy with CO2 Circulation

Journal of Investigative Surgery, 2018
Background: Closed hyperthermic intraperitoneal chemotherapy (HIPEC) may increase abdominal pressure and effects of hemodynamic changes due to maintenance hyperthermia.
Francisco Javier Redondo, David Padilla, Pedro Villarejo, Victor Baladron, Patricia Faba, Sergio Sánchez, José Ramón Muñoz-Rodríguez, Natalia Bejarano   +7 more
doaj   +1 more source

The prognosis impact of hyperthermic intraperitoneal chemotherapy (HIPEC) plus cytoreductive surgery (CRS) in advanced ovarian cancer: the meta-analysis

Journal of Ovarian Research, 2019
Background and objective Previous studies about the prognostic value of the HIPEC have yielded controversial results. Therefore, this study aims to assess the impact of HIPEC on patients with ovarian cancer.
Guyu Zhang, Yimin Zhu, Chongdong Liu, Guangming Chao, Ran Cui, Zhenyu Zhang   +5 more
doaj   +1 more source